BRENNEN

Industries / Health / Pharmaceuticals

Approval

Regulators deciding, from the evidence a company submits, whether a medicine may be sold.

7

Milestones achieved, from 1906 to 2023.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 1906

    The original US drug law

    The Food and Drugs Act, passed by Congress on 30 June 1906 and signed by President Theodore Roosevelt, banned interstate trade in misbranded and adulterated foods, drinks and drugs.

    fda.gov

    Credit

    US Congress; Theodore Roosevelt

  2. 1938

    Safety before sale

    In September and October 1937 a medicine called Elixir Sulfanilamide killed more than 100 people in 15 US states. The Federal Food, Drug, and Cosmetic Act of 1938 followed, requiring new drugs to be shown safe before they were sold.

    LessonUntil 1938 a new US drug did not have to be shown safe before sale, and it took mass deaths to change that.

    fda.govfda.gov

    Credit

    US Congress; FDA

  3. 1962

    Proof that a drug works

    The sleeping pill thalidomide caused birth defects in thousands of babies in western Europe. FDA medical officer Frances Kelsey had kept it off the US market by insisting on scientifically reliable evidence of safety. The Kefauver-Harris Amendments of 1962 then required drug makers, for the first time, to prove to the FDA that their products work before selling them.

    fda.govfda.gov

    Credit

    Frances Kelsey; US Congress

  4. 1990

    Three regions agree on rules

    ICH held its first meeting, of regulators and industry experts, in Brussels in 1990, hosted by EFPIA, the European federation of drug makers. It began with three regions, Europe, the US and Japan, and by 2020 had around 50 medicine authorities as members or observers, by EFPIA's count.

    efpia.eu

    Credit

    the founding regulators and industry groups; EFPIA as host

  5. 1992

    Fees that pay reviewers

    The Prescription Drug User Fee Act made drug makers pay fees when they file applications, and required the FDA to use the money to hire more reviewers.

    fda.gov

    Credit

    US Congress; FDA

  6. 1995

    One agency for the EU

    The European Medicines Agency was set up in 1995 to harmonise the work of the national medicine regulators of the European Union.

    ema.europa.eu

    Credit

    European Union

  7. 2023

    An approval taken back

    In April 2023 the FDA withdrew approval of Makena, a drug for reducing the risk of preterm birth. It had been approved in 2011 under accelerated approval, a faster route based on an early sign that a drug will help, and the required follow-up study did not confirm a benefit.

    LessonA fast approval on an early sign holds only if a later study confirms it.

    fda.gov

    Credit

    FDA Commissioner and Chief Scientist

Watch for

  1. An AI assistant for reviewers

    The FDA launched Elsa, a generative AI tool, to all its staff on 2 June 2025. It says the agency already uses Elsa to speed clinical protocol reviews, shorten scientific evaluations and pick high-priority inspection targets.

    Achieved whenan outside body, such as a government auditor, measures review time or accuracy with and without the tool and publishes the result.

    fda.gov

    Claimed by

    FDA, June 2025

  2. AI drafts of regulatory filings

    Anthropic reports that Claude wrote first drafts of two regulatory documents for Enveda. One took four hours, against about three months by hand; for the other, Enveda's standard human review found one minor error.

    Achieved whensuch drafts are tested on documents others can see, or a regulator reports on the quality of AI-drafted submissions.

    anthropic.com

    Claimed by

    Anthropic and Enveda, October 2026

Open

  1. 01

    Score AI drafts against EMA

    A benchmark in which an AI system reads the clinical data a company submitted to EMA, which EMA has made public, and drafts a summary of the medicine's results and risks. Experts score each draft against the facts in EMA's own published assessment of that medicine.

    The brief
    Credit · unclaimed
  2. 02

    Label every rejection letter

    An open table of every complete response letter the FDA has published (the letter it sends when it will not approve an application as filed), each labelled by kind of problem (factory inspection, product quality, effectiveness, safety, other) and linked to any later approval. Add a classifier that labels each new letter within a day of its posting.

    The brief
    Credit · unclaimed

Open 01 · the brief

Score AI drafts against EMA

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A benchmark in which an AI system reads the clinical data a company submitted to EMA, which EMA has made public, and drafts a summary of the medicine's results and risks. Experts score each draft against the facts in EMA's own published assessment of that medicine.

Why it is still open

Results for AI-drafted filings, such as Enveda's, are measured on private documents no one else can check. EMA has published companies' clinical data since October 2016, and after a pause resumed for medicines with new active substances from September 2023.

anthropic.comema.europa.eu

Built with what exists

EMA's clinical data publication website; EMA's published assessment reports; Claude, Gemini or an open-weight model; a scoring sheet; two reviewers.

  1. First step

    Pick two medicines with published clinical data and write their answer keys from EMA's assessments.

  2. Done looks like

    20 medicines; for each, at least 10 key facts (main results, effect sizes, main risks) scored right or wrong by two reviewers, with error rates for each kind of fact published.

Open 02 · the brief

Label every rejection letter

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

An open table of every complete response letter the FDA has published (the letter it sends when it will not approve an application as filed), each labelled by kind of problem (factory inspection, product quality, effectiveness, safety, other) and linked to any later approval. Add a classifier that labels each new letter within a day of its posting.

Why it is still open

The FDA began publishing these letters in July 2025, more than 200 at first, redacted, in a list on openFDA. The list gives the company, date and approval status, not the kind of problem.

fda.govopen.fda.gov

Built with what exists

the openFDA complete response letter table; approval dates from Drugs@FDA; Gemini Decision 1 or Claude to assign labels; two people to label a test set. The note "A thousand questions, one pass" covers Gemini Decision 1.

  1. First step

    Download the table, label 30 letters by hand and write down the labelling rules.

  2. Done looks like

    Every published letter labelled; on 100 letters labelled separately by two people, the classifier agrees with them at least 90% of the time; new letters labelled within 24 hours for one month.